KURA Key Statistics, Chart & Performance
The current stock price of KURA is 8.91 USD. In the past month the price decreased by -16.18%. In the past year, price increased by 22.73%.
KURA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KURA. When comparing the yearly performance of all stocks, KURA turns out to be only a medium performer in the overall market: it outperformed 57.25% of all stocks.
KURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KURA. The financial health of KURA is average, but there are quite some concerns on its profitability.
KURA Financial Highlights
Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS decreased by -5.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.4% | ||
| ROE | -89.42% | ||
| Debt/Equity | 0.02 |
KURA Forecast & Estimates
21 analysts have analysed KURA and the average price target is 33.66 USD. This implies a price increase of 277.78% is expected in the next year compared to the current price of 8.91.
For the next year, analysts expect an EPS growth of -31.54% and a revenue growth 1380.16% for KURA
KURA Ownership
KURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.08B | ||
| AMGN | AMGEN INC | 15.09 | 177.71B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.28 | 111.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.43 | 47.46B | ||
| INSM | INSMED INC | N/A | 33.97B | ||
| NTRA | NATERA INC | N/A | 33.17B | ||
| BIIB | BIOGEN INC | 10.07 | 24.73B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.83B | ||
| INCY | INCYTE CORP | 16.39 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 20.32B |
Related stock screener links
About KURA
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
Company Info
KURA ONCOLOGY INC
4930 Directors Place, Suite 500
San Diego CALIFORNIA 92130 US
CEO: Troy E. Wilson
Employees: 192
Phone: 18585008800
KURA ONCOLOGY INC / KURA FAQ
What does KURA ONCOLOGY INC do?
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
What is the stock price of KURA ONCOLOGY INC today?
The current stock price of KURA is 8.91 USD. The price decreased by -4.81% in the last trading session.
What is the dividend status of KURA ONCOLOGY INC?
KURA does not pay a dividend.
What is the ChartMill rating of KURA ONCOLOGY INC stock?
KURA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for KURA stock?
The Revenue of KURA ONCOLOGY INC (KURA) is expected to grow by 1380.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does KURA ONCOLOGY INC (KURA) report earnings?
KURA ONCOLOGY INC (KURA) will report earnings on 2026-02-24, after the market close.
What is the ownership structure of KURA ONCOLOGY INC (KURA)?
You can find the ownership structure of KURA ONCOLOGY INC (KURA) on the Ownership tab.